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with recurrent metastatic renal cell carcinoma. The patient had an excellent performance status. Blood tests showed haemoglobin of 11.3g/dL(range: 13.5 -18.0g/dL), corrected calcium 2.49mmol/l (range:2.05 -2.60mmol/l) and normal level serum lactate dehydrogenase. His metastatic renal cell carcinoma was stratified as intermediate risk according to both MSKCC and Hengcriteria. The patient was commenced on sunitinib at the standard dose of 50mg/day, 4 weeks on 2 weeks off (see graph: blue arrowhead).
Treatment with sunitinib was uneventful other than a dose reduction to 37.5mg after cycle four for persistent fatigue and development of subclinical RECIST criteria showed 18% enlargement from nadir. Sunitinib dose reescalation was attempted in order to regain disease control, however, subsequent scan showed unequivocal disease progression, with RECIST progression of 45% from nadir (see graph: red arrowhead). Clinically at this point, the patient also began demonstratinga deteriorationin functional status.
An attempt to commence on sorafenib was interrupted by hospital admission for acute pulmonary oedema which resolved with treatment. After consultation with the patient and his family, a decision was taken for best supportive care only and a routine follow up appointment was made in case he changed his Our report describes a case of sustained spontaneous regression upon cessation of sunitinib following unequivocal evidence of sunitinib resistance and disease progression. To date, there are only two other reports on similar phenomenon in the medical literature 6, 7 . In Yanagihara's case, the patient received less than two cycles of sunitinib due to significant toxicities and radiographic evidence of disease progression. Persistent regression was observed approximately eleven months after cessation of treatment. In the case described by Rothermundt et al, the patient had a progression-free period of eleven months. Disease regression was first noted in the 12 th month and persisted at the time of reporting two months later.
The mechanisms underlying such regression remain unclear and speculative.
Rothermundt et al drew comparison to anti-androgen withdrawal syndrome as seen in advanced prostate cancer. It was speculated that mutation in the androgen receptor could lead to antagonists acting as agonists 8 . Acquired mutation has also been observed in non-small cell lung cancers harbouring mutation in epithelial growth factor receptors (EGFR). In fact, the conversion Other proposed mechanisms include the immunomodulatory effect of sunitinib. It has long been known that renal cell carcinoma is a highly immunologic tumour and manipulation of the immune system towards a Th1 population with interferon and interleukin-2 has been able to induce prolonged disease control and even remission in selected patients. The presence of intratumoural regulatory T-cells has been correlated with poor survival 13 . The effect of sunitinib on the immune system has been actively studied. Sunitinib may inhibit proliferation of peripheral blood T-cells, arrest T-cell development and inhibits pro-inflammatory cytokines production from T-cells 14 . On the other hand, studies have demonstrated sunitinib's ability to reduce regulatory T-cell levels 15 . How these differential effects combine to alter the natural history of disease remains to be elucidated.
In our case, our patient enjoyed a progression-free survival of almost 20 months, on-going regression of hepatic lesion over 60 months since initiation of sunitinib and complete resolution of pulmonary metastases.The sustained remission is highly suggestive of an immune-mediated phenomenon. This is even more remarkable as late-stage disease might be more effective at evading host immunity. Spontaneous remission in previously-treated renal cell carcinoma has rarely been observed as compared to treatment-naïvecases.
In fact, therapeutic immunomodulation conferred only minimal response in second-line setting compared to up-front treatment. 16 .Also, potentially immunomodulated responses were frequently more pronounced in pulmonary lesions, as have been seen in our case as well. Of note, the differential responses exhibited by the pulmonary and hepatic metastases suggested different biological characteristics, as only the pulmonary metastases progressed on sunitinib while the latter continued to decrease in size.In fact, this was recently confirmed by demonstration of significant intratumour heterogeneity and mutational burden 12 Although the hepatic lesion in our case was biopsy-confirmed recurrence, the diagnosis of pulmonary metastases was based on clinical and radiographic grounds. However, the concurrent progression prior to initiation of sunitinib, the typical "cannonball" appearance on thoracic imaging and initial response to sunitinib render an alternative diagnosis, such as benign inflammatory lesions, less plausible in this clinical setting.
It is difficult to estimate how common the above-described phenomenon is, with a high likelihood of under-observation as second line therapies are regularly initiated instantly upon evidence of progression. Interestingly, the phase 3 RECORD-1 trial which compared everolimus plus best supportive care to placebo plus best supportive care in renal cell carcinoma progressed on VEGF inhibition recorded up to 10% of minor tumoural response in the control arm 17 despite not reaching RECIST criteria for partial response.
Conclusion
In summary, we have described the first case of sustained spontaneous regression following progression on anti-VEGF tyrosine kinase inhibitor in a disease where median overall survival for patients with intermediate risk group was 27 months 18 . We propose that a short washout period between therapies for asymptomatic patients with radiographic monitoring could potentially assist in identify cohort of patients with similar "anti-VEGF withdrawal" effect to further understand the biology and possible underlying mechanisms.
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Spontaneous regression of metastatic clear cell renal cell carcinoma is a rare but well-documented phenomenon. It is thought to be immunogenic in origin.
Immunologic response in second line setting, however, is uncommon. Modern tyrosine kinase inhibitors exert efficacy in renal cell carcinoma predominantly via inhibition of VEGF pathways but early pre-human studies have suggested that these agents exert effect on the immune system as well. Our case 
